2.57
0.00%
0.00
Vorhandelsmarkt:
2.61
0.04
+1.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire
Esperion's Cholesterol Drug Shows 25% LDL Reduction in Japan Trial, Advances to NDA | ESPR Stock News - StockTitan
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan
Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa
Esperion's chief commercial officer sells shares worth $426 - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright - MarketBeat
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - The Manila Times
Esperion Highlights New Exploratory Data from CLEAR - GlobeNewswire
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat
ESPR: 3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket - StockNews.com
Two Seas Capital LP Acquires Significant Stake in Esperion Thera - GuruFocus.com
Esperion Therapeutics: Growth Initiatives Are Paying OffBuy - Seeking Alpha
Esperion Therapeutics Q3 2024 Earnings Preview - MSN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates - MSN
What is HC Wainwright's Estimate for ESPR FY2025 Earnings? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
Esperion Therapeutics: Q3 Earnings Snapshot - Darien Times
Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo Finance
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times
Esperion Q3 Revenue Surges 52% to $51.6M as Prescription Growth Accelerates | ESPR Stock News - StockTitan
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Buy" - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com
Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire
Esperion Announces a Featured Presentation in the Late - GlobeNewswire
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance
Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat
Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Nexletol From Esperion - Pharmacy Times
Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com
Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
INVA: 3 Small-Cap Biotech Stocks With Game-Changing Potential - StockNews.com
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):